Gultekin Sukriye Cansu, Cakir Ahmet Burak, Guc Zeynep Gulsum, Ozalp Faruk Recep, Keskinkilic Merve, Yavuzsen Tugba, Karadibak Didem
Faculty of Physiotherapy and Rehabilitation, Graduate School of Health Sciences, Dokuz Eylul University, Izmir, Turkey.
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey.
BMC Womens Health. 2025 May 30;25(1):267. doi: 10.1186/s12905-025-03829-6.
Although upper limb (UL) functionality was reported to be adversely affected in patients with breast cancer- related lymphedema (BCRL), there is currently no validated, objective performance-based assessment tool designed to evaluate UL function in this population. The Upper Limb Functional Test (ULIFT) was adapted from the ADL test (TGlittre), which is widely used in clinical settings and research, and was developed to assess unilateral UL functionality. Therefore, the present study aimed to evaluate the psychometric properties of the ULIFT in patients with BCRL.
The study involved 36 women with unilateral BCRL and 30 healthy women controls. Intraclass correlation coefficients (ICC) were used to assess test-retest reliability. ULIFT was conducted a second time with 36 patients (100% of the total sample) over a period of 7 to 14 days for test-retest reliability analysis. The following measures were used to investigate ULIFT convergent validity: Range of motion was assessed using a universal goniometer; UL disability with the Disability of the Arm, Shoulder and Hand (DASH) questionnaire; hand grip strength with a Jamar dynamometer; and quality of life (QoL) with the Short Form 36-item Health Survey (SF-36) survey, and Upper Limb Lymphedema 27 (ULL-27). The receiver operating characteristic (ROC) curve analysis was conducted as part of the known-group validity assessment to establish a cut-off point for ULIFT in distinguishing between patients with BCRL and healthy controls.
The ULIFT showed excellent test-retest reliability [ICC [95%] 0.92 (0.86-0.96)], a standard error of measurement of 3.91 s, and a minimum detectable change of 10.83 s. The sensitivity of 72.2%, specificity of 73.3% and AUC of 0.773 indicate a moderate ability of ULIFT to discriminate patients with and without impairment at a cut-off of 110.125 s. Significant correlations were found between ULIFT and UL functional measures (r ≥ 0.3), indicating convergent validity.
ULIFT is a reliable and valid objective measurement tool for assessing unilateral UL function. The cut-off time of 110.125 s may help in clinical decision-making, particularly when used in conjunction with other assessments.
尽管据报道上肢(UL)功能在乳腺癌相关淋巴水肿(BCRL)患者中受到不利影响,但目前尚无经过验证的、基于客观表现的评估工具来评估该人群的上肢功能。上肢功能测试(ULIFT)改编自日常生活活动测试(TGlittre),后者在临床环境和研究中广泛使用,旨在评估单侧上肢功能。因此,本研究旨在评估ULIFT在BCRL患者中的心理测量特性。
该研究纳入了36名单侧BCRL女性患者和30名健康女性对照。组内相关系数(ICC)用于评估重测信度。36名患者(占总样本的100%)在7至14天内再次进行ULIFT以进行重测信度分析。采用以下测量方法来研究ULIFT的收敛效度:使用通用角度计评估关节活动范围;使用手臂、肩部和手部功能障碍(DASH)问卷评估上肢功能障碍;使用Jamar测力计评估握力;使用36项简短健康调查(SF-36)和上肢淋巴水肿27(ULL-27)评估生活质量(QoL)。作为已知组效度评估的一部分,进行了受试者操作特征(ROC)曲线分析,以确定ULIFT在区分BCRL患者和健康对照时的截断点。
ULIFT显示出出色的重测信度[ICC[95%]0.92(0.86 - 0.96)],测量标准误为3.91秒,最小可检测变化为10.83秒。灵敏度为72.2%,特异性为73.3%,曲线下面积(AUC)为0.773,表明ULIFT在截断值为110.125秒时区分有无功能障碍患者的能力中等。在ULIFT与上肢功能测量之间发现了显著相关性(r≥0.3),表明具有收敛效度。
ULIFT是一种可靠且有效的评估单侧上肢功能的客观测量工具。110.125秒的截断时间可能有助于临床决策,特别是与其他评估结合使用时。